Q32 Bio (QTTB) stock rocketed higher on Monday after the clinical-stage biotechnology company announced the sale of ADX-097 to Akebia Therapeutics (AKBA). ADX-097 is a Phase 2 complement inhibitor and the lead candidate from its tissue-targeted complement platform. It is designed to inhibit complement activation in a range of indications associated with C3d deposition including kidney, autoimmune, vascular, and skin diseases.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Q32 Bio noted that this sale will have Akebia Therapeutics take over all future development and costs related to ADX-097. The company will receive $12 million in upfront payments and a near-term milestone, including $7 million at signing, $3 million six months after the signing, and $2 million payable upon the achievement of a milestone or at the end of 2026. The total payments made to Q32 Bio could reach up to $592 million, and the agreement also includes tiered royalties on potential future sales ranging from the low single-digit to mid-teen percentages.
Q32 Bio said that the sale of ADX-097 provides the company with funds to continue development of its other projects. That includes its SIGNAL-AA Part A OLE and topline results of the SIGNAL-AA Part B trial, which are expected in mid-2026. The funds should last the company into the second half of 2027.
Q32 Bio Stock Movement
Q32 Bio stock was up 84.93% in pre-market trading on Monday, following a 6.31% rally yesterday. However, the stock has fallen 36.34% year-to-date and 91.77% over the past 12 months.
Today’s asset sale news resulted in heavy trading of QTTB stock, with more than 32 million shares exchanged as of this writing. That’s well above the company’s three-month daily average trading volume of about 396,000 units.
Is Q32 Bio Stock a Buy, Sell, or Hold?
Turning to Wall Street, the analysts’ consensus rating for Q32 Bio is Moderate Buy, based on one Buy and one Hold rating over the past three months. With that comes an average QTTB stock price target of $15, representing a potential 584.93% upside for the shares.
